Search research articles
Contact Us
Filters
Showing results (451-460 of 616) with videos related to
Page
of 62
Sort By:
European Journal of Heart Failure
|
November 25, 2025
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme
Ambarish Pandey, Michael Moroney, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
August 17, 2015
Knowledge, attitudes, and practice preferences of Canadian cardiac surgeons toward the management of acute type A aortic dissection
Mark D Peterson, Amine Mazine, Ismail El-Hamamsy, et al.
Cardiovascular Diabetology
|
October 5, 2021
Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
Bradley Sarak, Subodh Verma, C David Mazer, et al.
JACC. Heart Failure
|
May 25, 2023
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Muhammad Shahzeb Khan, Matthew W Segar, Muhammad Shariq Usman, et al.
JACC. Heart Failure
|
November 8, 2025
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study
Zainali Chunawala, Kershaw V Patel, Katelyn R Garcia, et al.
Journal of the American Heart Association
|
December 24, 2022
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
Muhammad Shahzeb Khan, Javed Butler, Stefan D Anker, et al.
JACC. Heart Failure
|
June 9, 2023
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Mikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
European Heart Journal
|
August 31, 2025
Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Brady Park, Fallon Dennis, Arianna Z He, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
August 31, 2013
Knowledge, attitudes, and practice patterns in surgical management of bicuspid aortopathy: a survey of 100 cardiac surgeons
Subodh Verma, Bobby Yanagawa, Sameer Kalra, et al.
Metabolism Open
|
August 20, 2020
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
Vinay Garg, Subodh Verma, Kim A Connelly, et al.
Page
of 62
Search research articles
Search
Showing results (451-460 of 616) with videos related to
Sort By:
Page
of 62
European Journal of Heart Failure
|
November 25, 2025
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme
Ambarish Pandey, Michael Moroney, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
August 17, 2015
Knowledge, attitudes, and practice preferences of Canadian cardiac surgeons toward the management of acute type A aortic dissection
Mark D Peterson, Amine Mazine, Ismail El-Hamamsy, et al.
Cardiovascular Diabetology
|
October 5, 2021
Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
Bradley Sarak, Subodh Verma, C David Mazer, et al.
JACC. Heart Failure
|
May 25, 2023
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Muhammad Shahzeb Khan, Matthew W Segar, Muhammad Shariq Usman, et al.
JACC. Heart Failure
|
November 8, 2025
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study
Zainali Chunawala, Kershaw V Patel, Katelyn R Garcia, et al.
Journal of the American Heart Association
|
December 24, 2022
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
Muhammad Shahzeb Khan, Javed Butler, Stefan D Anker, et al.
JACC. Heart Failure
|
June 9, 2023
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Mikhail N Kosiborod, Steen Z Abildstrøm, Barry A Borlaug, et al.
European Heart Journal
|
August 31, 2025
Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Brady Park, Fallon Dennis, Arianna Z He, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
August 31, 2013
Knowledge, attitudes, and practice patterns in surgical management of bicuspid aortopathy: a survey of 100 cardiac surgeons
Subodh Verma, Bobby Yanagawa, Sameer Kalra, et al.
Metabolism Open
|
August 20, 2020
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
Vinay Garg, Subodh Verma, Kim A Connelly, et al.
Page
of 62